ClinicalTrials.gg
RecruitingNCT05478876CYCLEUpdated Aug 21, 2024

Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract

An interventional study of carbon ion radiation therapy CIRT in Malignant Melanoma and Gynecologic Cancer, sponsored by CNAO National Center of Oncological Hadrontherapy. Recruiting at 1 site in Italy. Open to female participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by CNAO National Center of Oncological Hadrontherapy · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Sep 2020, registered Dec 2021).
  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
20 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 268 studies in Melanoma with a site in Italy — 47 open to participants now, 80 under way, 22 of them phase 3. Melanoma · Italy.

Planned enrollment
229th of 236
9 · median 191
Started
2020
with 16 others
No phase
20 of 268
12 open now
Primary completion
2027-09
later than 47 of 79 live
Registered
197th of 268
by date

Among the 268 studies in Melanoma with a site in Italy, this one is the 229th largest by planned enrollment of the 236 interventional ones that give a count, is one of 17 that started in 2020, is one of 20 with no phase, reaches primary completion later than 47 of the 79 other live ones, and was the 197th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

47 of the 268 studies in Melanoma with a site in Italy are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 20 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 268 studies in Melanoma with a site in Italy, or all of them as a file.
02

Study summary

The present monocentric prospective phase 2 study aims to reproduce the results obtained at NIRS thus offering the possibility of obtaining a promising rate of progression-free survival (PFS) and local control (LC) in patients diagnosed with mucosal melanoma of lower genital tract. Systemic treatment with immunotherapy is not the subject of this study but is allowed both in the neoadjuvant and sequential regimens.

Melanomas have always been considered poorly radiosensitive. It is now accepted that high LET (Linear Energy Transfer) particle beams, such as carbon ions, can offer a biological advantage, compared to photons treatment, in radio-resistant neoplasms treatment, thanks to their higher biological efficacy (RBE) against tumours with a low α/ ß ratio. In addition, carbon ions have the physical advantage of an inverted depth deposition profile compared to photons, allowing then a steep dose gradients that ensure increased sparing of adjacent healthy organs at risk (OARs).

Read the detailed description

Patients with primary gynaecological melanoma, non-metastatic, non-suitable for surgery, and not previously subjected to conventional radiotherapy can be enrolled in the trial, according to selection criteria. After requested baseline exams, the patient undergoes to simulation phase for the carbon ion radiation therapy, according to study constraints. The patient will then receive immunotherapy not concomitant to CIRT. The response is evaluated through RECIST criteria.

PFS is the primary endpoint, calculated from the end of CIRT to date of disease progression or death or last follow up.

03

Conditions studied

  • Malignant Melanoma
  • Gynecologic Cancer

Browse trials for

Keywords

  • hadrontherapy, gynecological melanoma
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis
  • Absence of skin extension
  • N + (only if confined to the groin and pelvis)
  • Age between 20-80 years
  • 0-2
  • No evidence of
  • At least 5 mm away with rectum and bladder wall
  • No previous RT
  • Written
  • Patient's ability to understand the characteristics and consequences of the clinical trial
  • Molecular characterization/ mutational state
  • Disease staging (baseline exams)

Exclusion criteria

Exclusion Criteria:

  • Hip prosthesis, or metal prostheses or any other condition that prevents adequate imaging to identify the target volume and calculate the dose in the treatment plan
  • Psychic or other disorders that may prevent
  • Previous invasive tumor unless patient has been disease free for at least 3 years
  • to MRI
  • Pregnancy or breastfeeding in progress
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    carbon ion radiotherapy

    Patients affected by pelvic recurrence of gynecological cancer, who had not undergone to previous pelvic irradiation, will be enrolled on this study. After enrollment, patients undergo baseline exams, simulation CT and MRI and then carbon ion radiation therapy treatment will be performed, according to trial indications.

    Radiation: carbon ion radiation therapy CIRT

Interventions

  • Radiationcarbon ion radiation therapy CIRT

    CIRT: The low-dose CTV (clinical target volume) will receive a total dose of 43 GyRBE in 10 fractions, 4 fractions per week. The high-dose CTV will receive a total dose of 68.8 GyRBE in 16 fractions, 4 fractions per week. The expected duration of treatment is 4 weeks, 4 fractions per week. Treatments lasting longer than 6 weeks, or with less than 6 fractions administered on 14 consecutive days, will not be considered acceptable. Immunotherapy: Patients will undergo immunotherapy after carbon ion radiation therapy (CIRT) up to maximum response and/or up to tolerance. The concomitant association of immunotherapy is not envisaged in this protocol.

    Also known as: immunotherapy

06

What researchers measure

Primary outcomes

  1. progression free survival

    estimate 2-year PFS in patients diagnosed with mucosal melanoma of the lower genital tract, treated with carbon ion radiation therapy.

    Time frame: 2 years

Secondary outcomes

  1. Overall survival (OS)

    The OS will be calculated from the end date of therapy with carbon ion radiation

    Time frame: 3 years

  2. Toxicity according to Common Terminology Criteria for Adverse Events (CTCAE version 5.0)

    acute, medium term and late toxicity

    Time frame: within 3 months, 3-6 months, over 6 months from CIRT

  3. local response

    according to Response Evaluation Criteria in Solid Tumours RECIST 1.1

    Time frame: 3 years

  4. assessment of quality of life

    assessed through questionarie Portec 3 administered on each follow up

    Time frame: 3 years

  5. assessment of quality of life for >= 75 years old patients

    assessed through questionnaire G8 Geriatric questionnaire administered on each follow up

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Sep 2027, 84 months after the start.

Of 220 non-industry interventional studies with no phase under Melanoma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 84 months is above that.

Counting every sponsor, half of 228 studies reached it within 38 months; a quarter within 20 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2021
First posted
Jul 28, 2022
StartActual
Sep 3, 2020
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05478876
Lead sponsor
CNAO National Center of Oncological Hadrontherapy
Responsible party
Sponsor
First posted
Jul 28, 2022
Start date
Sep 3, 2020
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 21, 2024

Study contacts

Amelia Barcellini, MD
Contact
amelia.barcellini@cnao.it
0039 0382078501
Cristina Bono, MSc
Contact
cristina.bono@cnao.it
0382078613
Amelia Barcellini, MD
principal investigator · CNAO National Center of Oncological Hadrontherapy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion